Skip to main contentAI and Advanced
/
BLISSGVS · BSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
BL
BSE · Equity shares · Biotechnology & Drugs182.88 · 0.24%
Bliss GVS Pharma BLISSGVS
NSE:INR 493.65
BSE:INR 688
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for BLISSGVS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 505.12
Day rangeINR 449.75 — INR 465.3
52-week rangeINR 118.35 — INR 733.75
Volume3.83 L
Market cap5,298.23
P/E17.63
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)927.11
Net Income (INR Cr)129.13
Rev Growth (5 Year %)9.94
EPS Growth (5 Year %)13.07
P/E Ratio17.63
Book Value112.01
EPS12.34
Price/BV6.14Computed
Research path: Interpret Bliss GVS Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BLISSGVSBliss GVS Pharma1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,492.41 | 1,301.29 | 1,213.87 |
| Accumulated Depreciation Total | -147.55 | -124.39 | -96.79 |
| Cash Equivalents | 12.69 | 13.26 | 5.62 |
| Other Liabilities Total | 11.81 | 4.41 | 2.6 |
| Accrued Expenses | 4.44 | 3.96 | 4.57 |
| Long Term Debt | 0 | 19.85 | 35.59 |
| Common Stock Total | 10.58 | 10.54 | 10.47 |
| Other Equity Total | -4.55 | -18.17 | -15.84 |
| Other Current Assets Total | 29.21 | 71.99 | 75.81 |
| Prepaid Expenses | 4.17 | 2.47 | 2.78 |
| Total Assets | 1,492.41 | 1,301.29 | 1,213.87 |
| Current Portof LT Debt/Capital Leases | 5.7 | 32.65 | 22.85 |
| Additional Paid-In Capital | 44.79 | 40.42 | 33.2 |
| Cash | 22.45 | 10.53 | 17.52 |
| Total Equity | 1,192.9 | 1,050.38 | 967.19 |
| Long Term Investments | 34.62 | 31.75 | 8.7 |
| Retained Earnings(Accumulated Deficit) | 1,142.08 | 1,017.59 | 939.37 |
| Total Common Shares Outstanding | 10.58 | 10.54 | 10.47 |
| Property/Plant/Equipment Total-Gross | 604.28 | 542.1 | 466.17 |
| Tangible Book Valueper Share Common Eq | 112.01 | 98.93 | 91.64 |
| Goodwill Net | 7.71 | 7.71 | 7.71 |
| Total Liabilities | 299.51 | 250.91 | 246.68 |
| Total Debt | 21.75 | 88.1 | 99.84 |
| Short Term Investments | 153.49 | 117.55 | 128.16 |
| Cashand Short Term Investments | 188.64 | 141.34 | 151.3 |
| Total Receivables Net | 571.6 | 472.36 | 445.15 |
| Notes Payable/Short Term Debt | 2.75 | 22.89 | 32.12 |
| Deferred Income Tax | 0 | 0.3 | 3.59 |
| Accounts Receivable-Trade Net | 525.23 | 447.28 | 404.35 |
| Property/Plant/Equipment Total-Net | 456.73 | 417.72 | 369.38 |
| Minority Interest | 38.86 | 41.47 | 35.79 |
| Total Current Liabilities | 235.54 | 172.16 | 159.82 |
| Total Inventory | 152.73 | 128.5 | 136.59 |
| Accounts Payable | 104.21 | 71.42 | 60.97 |
| Other Currentliabilities Total | 118.44 | 41.24 | 39.31 |
| Total Long Term Debt | 13.3 | 32.56 | 44.87 |
| Intangibles Net | 0.21 | 0.23 | 0.11 |
| Other Long Term Assets Total | 37.11 | 11.98 | 3.78 |
| Note Receivable-Long Term | 9.7 | 15.24 | 12.57 |
| Total Current Assets | 946.34 | 816.66 | 811.62 |
| Capital Lease Obligations | 13.3 | 12.72 | 9.28 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.94
Price to Sale Ratio5.71
Growth
Debt 5Yr CAGR %-29.16
Margins
Operating Margin 12m12.55
Operating Margin 5y Avg11.14
Net Profit Margin 12m14.53
Net Profit Margin 5y10.15
Yield
Dividend Yield %0.3
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.88
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 35.01%
- FII
- 8.07%
- MF
- 0.26%
- Other
- 56.66%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Anupam Rasayan adds Mates Visa as PAC for Bliss GVS Pharma open offer - scanx.tradeMarket news · 19 Jul 2026, 7:19 pm
Anupam Rasayan adds Mates Visa as PAC for Bliss GVS Pharma open offer scanx.trade
Anupam Rasayan acquires Mates Visa for Bliss GVS deal - scanx.tradeMarket news · 17 Jul 2026, 11:02 pm
Anupam Rasayan acquires Mates Visa for Bliss GVS deal scanx.trade
Bliss GVS Pharma (506197) Q2 25/26 earnings summary - QuartrMarket news · 15 Jul 2026, 9:48 pm
Bliss GVS Pharma (506197) Q2 25/26 earnings summary Quartr
Bliss GVS Pharma declares Re. 1.00 final dividend for FY26 - scanx.tradeMarket news · 15 Jul 2026, 9:08 pm
Bliss GVS Pharma declares Re. 1.00 final dividend for FY26 scanx.trade
Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 - marketscreener.comMarket news · 15 Jul 2026, 9:07 pm
Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 marketscreener.com
Bliss GVS Pharma - Multibaggers: 13 stocks surged up to 225% in just 3 months - The Economic TimesMarket news · 10 Jul 2026, 4:40 pm
Bliss GVS Pharma - Multibaggers: 13 stocks surged up to 225% in just 3 months The Economic Times
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.0000 per share(100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- dividendRs.0.5000 per share(50%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- annual General MeetingPOM
Rusaka Markets Community
Discussion and sentiment for Bliss GVS Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BLISSGVS
- BSE Code
- 506197
Questions
Stock FAQ
What is the symbol and ISIN of Bliss GVS Pharma?
Bliss GVS Pharma has the symbol BLISSGVS and ISIN - INE416D01022.
What is the current price of Bliss GVS Pharma?
Bliss GVS Pharma is currently trading at INR 688.00.
What are the year high and year low of Bliss GVS Pharma?
Bliss GVS Pharma has a year high of INR 733.75 and a year low of INR 118.35.
What is the market capitalization of Bliss GVS Pharma?
Bliss GVS Pharma has a market capitalization of INR 5,298.23 crore.
What is the P/E ratio of Bliss GVS Pharma?
Bliss GVS Pharma has a P/E ratio of 17.63.
What is the dividend yield of Bliss GVS Pharma?
Bliss GVS Pharma has a dividend yield of 0.30%.
How is the financial performance of Bliss GVS Pharma based on revenue, net income, and EPS?
Bliss GVS Pharma has revenue of INR 927.11 crore, net income of INR 129.13 crore, and EPS of INR 12.14.
What is the book value of Bliss GVS Pharma?
Bliss GVS Pharma has a book value of INR 112.01.
What is the debt-to-equity ratio of Bliss GVS Pharma?
Bliss GVS Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Bliss GVS Pharma?
Bliss GVS Pharma has a price-to-book ratio of 6.14 and a price-to-sales ratio of 5.71.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.